A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
- Kefford, Richard (Primary Chief Investigator)
- Butala, Radhika (Associate Investigator)
- Cunningham, Jacob (Associate Investigator)
Project: Other